U.S. License Holder:
Date of License:
ZEVALIN (ibritumomab tiuxetan) is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of patients with:
Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL);
Previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy.